Respiratory General Medicine Strong — GOLD 2023 / NICE NG115
GOLD COPD Classification
GOLD 2023 ABCD assessment tool for COPD combining symptom burden (CAT/mMRC) and exacerbation history to guide therapy.
References
- GOLD 2023 Global Strategy for Prevention, Diagnosis and Management of COPD. Global Initiative for Chronic Obstructive Lung Disease.
- NICE NG115. Chronic obstructive pulmonary disease in over 16s. 2019.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Fluticasone Furoate / Umeclidinium / Vilanterol · Triple Therapy ICS/LAMA/LABA — COPD
- Beclometasone / Formoterol / Glycopyrronium · Triple Therapy ICS/LABA/LAMA — COPD
- Indacaterol / Glycopyrronium · LABA/LAMA Dual Bronchodilator — COPD
- Azithromycin (COPD Exacerbation Prophylaxis) · Macrolide antibiotic (anti-inflammatory / prophylactic)
- Doxycycline (COPD Exacerbation / CAP) · Oral tetracycline antibiotic
- Co-amoxiclav 625mg (COPD Exacerbation / CAP) · Beta-lactam / Beta-lactamase inhibitor combination antibiotic
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
- Community-Acquired Pneumonia (CURB-65) · BTS 2009 / NICE NG138
- Acute Pulmonary Embolism · BTS 2003 / ESC 2019
- Pleural Effusion Assessment · BTS 2010
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.